Trihexyphenidyl, an anticholinergic medication commonly prescribed for Parkinson's symptoms, appears to alleviate negative memory flashbacks and nightmares experienced by those with PTSD.
As interest in using psychedelics to treat a range of mental health disorders grows, researchers consider the impact and therapeutic benefits of using psychedelics to help alleviate symptoms of depression.
Fenofibrate, a drug developed to control cholesterol, alleviated brain and behavioral abnormalities in mouse models of schizophrenia.
Ezogabine, a drug that opens up the KCNQ2/3 type potassium channel, significantly improved symptoms of depression and anhedonia.
From microdosing to improve cognition, to treating a range of mental health disorders, researchers evaluate the rise in the use of psychedelics and their potential as medicines.
A new small scale study reveals the antidepressant fluvoxamine may be a new tool in the fight against COVID-19. Researchers report fluvoxamine reduced the severity of coronavirus symptoms and hospitalizations.
Degarelix, a drug that reduces testosterone levels, shows potential in the treatment of pedophilic disorder. Men with a history of child sexual abuse who took the drug had reduced overall sexual desire and decreased attraction toward children, with noticeable effects within two weeks.
Fish model study found a potential target for the treatment of seasonal affective disorder (SAD). Researchers implicated NRF2 in seasonal depression and reported celastrol may help in the treatment of SAD.